Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects

Eur J Med Chem. 2018 Jan 1:143:1428-1435. doi: 10.1016/j.ejmech.2017.10.038. Epub 2017 Oct 18.

Abstract

Heat shock protein 90 (Hsp90) is a chaperone under investigation for the treatment of cancer and neurodegenerative diseases. Neuroprotective Hsp90 C-terminal inhibitors derived from novobiocin (novologues) include KU-32 and KU-596. These novologues modulate molecular chaperones and result in an induction of Heat Shock Protein 70 (Hsp70). "Noviomimetics" replace the synthetically complex noviose sugar with a simple cyclohexyl moiety to maintain biological efficacy as compared to novologues KU-596 and KU-32. In this study, we further explore the development of noviomimetics and evaluate their efficacy using a luciferase refolding assay, immunoblot analysis, a c-jun assay, and an assay measuring mitochondrial bioenergetics. These new noviomimetics were designed and synthesized and found to induce Hsp70 and improve biological activity. Noviomimetics 39e and 40a were found to induce Hsp70 and exhibit promising effects in cellular assays.

Keywords: Heat shock protein 70; Heat shock protein 90; Molecular chaperones; Neurodegeneration; Noviomimetics; Novologues.

MeSH terms

  • Cell Line
  • Dose-Response Relationship, Drug
  • Drug Discovery*
  • HSP90 Heat-Shock Proteins / chemistry
  • HSP90 Heat-Shock Proteins / metabolism*
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Models, Molecular
  • Neuroprotective Agents / chemistry*
  • Neuroprotective Agents / pharmacology*
  • Novobiocin / chemistry*
  • Novobiocin / pharmacology*
  • Protein Conformation

Substances

  • HSP90 Heat-Shock Proteins
  • Neuroprotective Agents
  • Novobiocin